Growth Hormone Deficiency: LAGH Data Visualization
After participating you can claim your CME credit here: https://forms.gle/C4kHxjXBJLFQR29TA
Accreditation: 0.25 AMA PRA Category 1 Credits™
Learning objectives
1. Evaluate patients with suspected GHD by integrating clinical presentation, laboratory findings, and genetic testing:
- Differentiate GHD from other conditions with similar symptoms to ensure accurate and timely diagnosis in both pediatric and adult patients.
- Utilize appropriate diagnostic tests and interpret the results in the context of each patient’s clinical profile. Collaborate with specialists, when needed, to confirm the diagnosis and streamline the referral process for comprehensive care.
2. Select appropriate candidates for transitioning from daily GH therapy to LAGH based on clinical criteria and patient needs:
- Assess patient adherence challenges, comorbidities, and treatment goals to determine suitability for LAGH.
- Effectively communicate with patients and caregivers to set realistic expectations and improve long-term adherence to LAGH therapy.
- Monitor and adjust LAGH therapy in line with individual patient responses to optimize outcomes.
3. Implement individualized IGF-I monitoring strategies to optimize therapy for patients receiving daily GH or LAGH:
- Interpret fluctuations in IGF-I levels to make data-driven decisions on dosing and therapy adjustments.
- Tailor monitoring approaches based on the pharmacokinetic and pharmacodynamic differences between daily GH and LAGH therapies.
- Apply long-term surveillance data to ensure patient safety, efficacy, and adherence during treatment
This program is supported by an independent education grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.
Continuing Education Information
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Disclosures Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Kevin Yuen is an Advisory Board Member for Novo Nordisk, Ascendis, Chiesi and Crinetics. His institution has received research grants from Ascendis and Novo Nordisk. He is an occasional speaker for Novo Nordisk. He has no unapproved product related discussions to disclose.
Bradley Miller is a consultant for Amgen, Ascendis Pharma, BioMarin, Eton Pharmaceuticals, Novo Nordisk, Pfizer, Soleno and Tolmar and has received research support from Alexion, Abbvie, Aeterna Zentaris, Foresee, Lumos Pharma, Novo Nordisk, OPKO Health, and Pfizer. He has no unapproved product related discussions to disclose.
Sasigarn Bowden’s institution has received research funding from Ultragenyx, Lumos Pharma and Biomarin. She has no unapproved product related discussions to disclose.
AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.
Mitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.
Other Professionals All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
This program is supported by an independent education grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.
Continuing Education Information
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Faculty Prof Bradley Miller, Prof Sasigarn Bowden & Prof Kevin Yuen
Disclosures Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Kevin Yuen is an Advisory Board Member for Novo Nordisk, Ascendis, Chiesi and Crinetics. His institution has received research grants from Ascendis and Novo Nordisk. He is an occasional speaker for Novo Nordisk. He has no unapproved product related discussions to disclose.
Bradley Miller is a consultant for Amgen, Ascendis Pharma, BioMarin, Eton Pharmaceuticals, Novo Nordisk, Pfizer, Soleno and Tolmar and has received research support from Alexion, Abbvie, Aeterna Zentaris, Foresee, Lumos Pharma, Novo Nordisk, OPKO Health, and Pfizer. He has no unapproved product related discussions to disclose.
Sasigarn Bowden’s institution has received research funding from Ultragenyx, Lumos Pharma and Biomarin. She has no unapproved product related discussions to disclose.
AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.
Mitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.
Other Professionals All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.